Given the effects of STING agonists in HFD-induced obese mice [41], it is plausible to hypothesize that DsbA-L may inhibit the cGAS-STING pathway in T cells, potentially suppressing the development and progression of diabetes. Here, STING1 is linked to diabetes mellitus.